Accumetrics is at the forefront of revolutionizing the way doctors manage the tens of millions of patients who take antiplatelet drugs to prevent heart attack, stroke and other potentially life-threatening cardiovascular events.

Accumetrics, a privately-held company based in San Diego, California, was founded in 1996, sold to Radiometer in 2000, and repurchased by company management and investors in 2003. The company employs over 80 people, and develops, manufactures, and markets the VerifyNow System, a comprehensive suite of assays for the assessment of platelet function. The assays are fully automated and easy-to-use allowing physicians an accurate way to assess platelet function to optimize the effectiveness of antiplatelet therapies, and to guide treatment decisions in patients who may be at risk of a life threatening thrombosis event or bleeding complication.